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Diabetes mellitus is a chronic condition with an increasing 
prevalence estimated to be 4.4% worldwide in 2030, the 
equivalent to 366 million people. Around one-third of 
diabetic patients are expected to develop painful diabetic 
neuropathy (PDN), which is the most disabling and costly 
complication of diabetes.  
Spinal cord stimulation (SCS) is a recognised 
neuromodulation technique for the management of 
neuropathic pains such as complex regional pain syndrome 
1 and failed back surgery syndrome. 2 Recently it has been 
reported that SCS results in significantly reduced pain and 
improved quality of life in patients with refractory painful 
diabetic neuropathy.3  The quality of life (QoL) analysis was 
based on the EQ-5D visual analogue scale scores.  We 
have now evaluated QoL based on index values of the EQ-
5D for the countries where this trial was conducted. 
Introduction 
The methods used, patient demographics and results from 
the randomised controlled trial are reported elsewhere.3 
Quality of life was assessed using the EQ-5D questionnaire. 
Health-related quality of life was derived from participants’ 
responses to the widely used EuroQoL EQ-5D-3L 
questionnaire. Responses were converted into single (utility) 
indices using the Dutch tariff.  Paired samples t-test were 
conducted to evaluate within group QoL changes. An 
ANCOVA analysis was undertaken to compare QoL 
between the groups while adjusting for the baseline score. 
Changes in sub-categories of the EQ-5D-3L were evaluated 
through the Mann-Whitney test for between-group analyses 
and the Wilcoxon signed-rank test for within-group 
analyses. Statistical analyses were conducted using the 
statistical software STATA (Release 13; College Station, TX: 
StataCorp LP).  
SCS has the potential to be an alternative for the management of refractory PDN. 
In addition to the significant reduction in pain observed in the de Vos et al RCT, 
SCS also appears to lead to significant improvements in QoL in this population. An 
economic evaluation is now in progress to evaluate the cost-effectiveness of SCS 
for the management of refractory PDN. 
Conclusion 
Methods 
References 
1. Kemler MA, Barendse GA, van Kleef M, de Vet HC, et al. N Engl J Med 2000; 343: 618-24. 
2. Kumar K, Taylor RS, Jacques L, Eldabe S, et al. Pain 2007; 132: 179-88. 
3. de Vos CC, Meier K, Zaalberg PB, Nijhuis HJ, et al. Pain 2014; 155: 2426-31. 
Results 
No statistically significant 
improvements were observed for the 
CMP group between baseline and six-
month follow-up for the VASPI, EQ-5D 
utility or EQ-5D VAS scores (Table 1). 
Statistically significant improvements 
were observed for all outcome 
measures for the patients in the SCS 
group between baseline and six-
month follow-up. Patients randomised 
to SCS experience greater pain relief 
and grater improvement in QoL as 
measured by the EQ-5D utility scores 
and EQ-5D VAS than those patients 
randomised to CMP. The interaction 
between groups and QoL baseline 
score was not significant 
F(1,50)=2.391, p=0.128. The ANCOVA 
comparing QoL between groups while 
adjusting for the baseline score was 
significant F(1,50) = 14.274, p<0.001. 
On the EQ-5D sub-categories, at six-
months the patients randomised to 
SCS reported significant 
improvements in four out of five 
dimensions: mobility, usual activities, 
pain/discomfort and 
anxiety/depression when compared to 
baseline (Figure 1). Statistically 
significant differences were observed 
between groups for the 
pain/discomfort EQ-5D dimension.  
Figure 1. Comparison of proportion of patients reporting some problems or extreme 
problems in the EQ-5D subcategories  
